ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

CORRECT(12/13): FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment

("FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment" on Dec. 13 and an earlier story on Jan. 18 misstated that Valeant Pharmaceuticals International Inc. is currently a commercial partner for the drug. A corrected version follows:) DOW JONES NEWSWIRES Alexza Pharmaceuticals Inc. (ALXA) said a U.S. Food and Drug Administration panel has recommended that its schizophrenic and bipolar disorder treatment be approved for use. Shares were recently up 76% to $1.10 as the company's chief executive called the panel's recommendation "another step forward" for the drug's development. Alexza in August said it refiled its new drug application for the treatment, adding new data and sections that aimed to address safety concerns raised by the agency last year. "If approved, we believe Adasuve represents a valuable treatment option for patients and physicians alike. We look forward to continuing to work toward our goal of bringing Adasuve to market in 2012," said Chief Executive Thomas B. King. Alexza last month reported its third-quarter loss widened sharply from a year earlier as it recorded higher research and development expenses and a loss on a contingent liability. -By Mia Lamar, Dow Jones Newswires; 212-416-3207;

Stock News for Valeant Pharma (VRX)
11/24/201516:21:51Statement of Changes in Beneficial Ownership (4)
11/24/201509:48:00U.S. Hot Stocks: Hot Stocks to Watch
11/24/201503:02:00Ackman's Pershing Buys More Of Valeant
11/23/201518:20:00Ackman's Pershing Square Boosts Stake in Valeant to 9.9%
11/23/201517:14:20Amended Statement of Beneficial Ownership (sc 13d/a)
11/23/201507:50:00Pfizer and Allergan Strike Huge Inversion Deal
11/22/201520:40:00Pfizer, Allergan Agree to Merge
11/22/201520:37:00Concerns Over Valeant Spread to Other Drug Makers
11/21/201513:00:033 Stocks Wall Street Hates
11/20/201517:43:47EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class...
11/20/201512:44:03Bill Ackman's Pershing Square Hedge Fund Is Hanging On to This...
11/20/201510:30:00VRX Investor Deadline Alert: Law Offices of Howard G. Smith Reminds...
11/20/201510:26:00/C O R R E C T I O N -- Valeant Pharmaceuticals International...
11/20/201510:26:00/C O R R E C T I O N -- Valeant Pharmaceuticals International...
11/20/201508:41:03How 1 Specialty-Drug Maker Hopes to Win Back Investor Trust
11/20/201508:39:03Should You Own Lone Pine Capital's 3 Favorite Stocks?
11/20/201508:00:00Valeant To Hold Investor Day On December 16
11/20/201508:00:00Valeant To Hold Investor Day On December 16
11/19/201517:10:00Valeant Share Price Surges on Citigroup Recommendation

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations